(Q30326336)

English

Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

1 reference

Europe PubMed Central

Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

author name string

Merenich JA

1

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

Lousberg TR

2

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

Brennan SH

3

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

Calonge NB

4

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

language of work or name

0 references

publication date

1 February 2000

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

85

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

3A

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

36A-42A

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

Statin trials and goals of cholesterol-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

A case-management system for coronary risk factor modification after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900937-6

7 January 2021

Identifiers

10.1016/S0002-9149(99)00937-6

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30326336&oldid=1612156919"